These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33897617)

  • 1. Mining Gut Microbiota From Bariatric Surgery for MAFLD.
    Wu WK; Chen YH; Lee PC; Yang PJ; Chang CC; Liu KL; Hsu CC; Huang CC; Chuang HL; Sheen LY; Liu CJ; Wu MS
    Front Endocrinol (Lausanne); 2021; 12():612946. PubMed ID: 33897617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.
    Rochoń J; Kalinowski P; Szymanek-Majchrzak K; Grąt M
    World J Gastroenterol; 2024 Jun; 30(23):2964-2980. PubMed ID: 38946874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
    Cornejo-Pareja I; Amiar MR; Ocaña-Wilhelmi L; Soler-Humanes R; Arranz-Salas I; Garrido-Sánchez L; Gutiérrez-Repiso C; Tinahones FJ
    J Gastroenterol; 2024 Apr; 59(4):329-341. PubMed ID: 38265508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery.
    Martínez-Montoro JI; Kuchay MS; Balaguer-Román A; Martínez-Sánchez MA; Frutos MD; Fernández-García JC; Ramos-Molina B
    Obes Rev; 2022 Feb; 23(2):e13367. PubMed ID: 34729904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis.
    Cerreto M; Santopaolo F; Gasbarrini A; Pompili M; Ponziani FR
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients.
    Pérez-Rubio Á; Soluyanova P; Moro E; Quintás G; Rienda I; Periañez MD; Painel A; Vizuete J; Pérez-Rojas J; Castell JV; Trullenque-Juan R; Pareja E; Jover R
    Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The microbial metabolome in metabolic-associated fatty liver disease.
    Li M; Rajani C; Zheng X; Jia W
    J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease.
    Dongoran RA; Tu FC; Liu CH
    Tzu Chi Med J; 2023; 35(4):290-299. PubMed ID: 38035056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation.
    Abenavoli L; Gambardella ML; Scarlata GGM; Lenci I; Baiocchi L; Luzza F
    Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota.
    Cai T; Song X; Xu X; Dong L; Liang S; Xin M; Huang Y; Zhu L; Li T; Wang X; Fang Y; Xu Z; Wang C; Wang M; Li J; Zheng Y; Sun W; Li L
    Front Cell Infect Microbiol; 2024; 14():1323261. PubMed ID: 38444539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.
    Oh JH; Lee JH; Cho MS; Kim H; Chun J; Lee JH; Yoon Y; Kang W
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33801023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
    Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
    Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.
    Wang YY; Lin HL; Wang KL; Que GX; Cao T; Zhu LM; Yang X; Yang XF
    Chin Med Sci J; 2023 Dec; 38(4):286-296. PubMed ID: 38097345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic-Associated Fatty Liver Disease and the Gut Microbiota.
    Barber TM; Hanson P; Weickert MO
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):485-496. PubMed ID: 37495339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
    Ni Y; Ni L; Zhuge F; Fu Z
    Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin C and vitamin D
    Chen Q; Zhao L; Mei L; Zhao X; Han P; Liu J; Meng C; Li R; Zhong R; Wang K; Li J
    Front Pharmacol; 2023; 14():1163694. PubMed ID: 37089915
    [No Abstract]   [Full Text] [Related]  

  • 20. Mid-term Effects of Bariatric Surgery on Metabolic Dysfunction-Associated Fatty Liver Disease Remission and Predictive Factors: A Prospective Study with a Focus on Non-invasive Diagnosis.
    Navarro-Masip È; Mestres N; Zorzano-Martínez M; Salinas-Roca B; Sánchez E; López-Cano C; Herrerías F; de la Fuente MC; Santamaría M; León-Mengíbar J; Soler AG; Bueno M; Lecube A
    Obes Surg; 2024 Mar; 34(3):841-849. PubMed ID: 38285299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.